B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, S Gumeni, P Malandrakis, E-D Papanagnou, M Migkou, N Kanellias, E Kastritis, I P Trougakos, M A Dimopoulos
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000829572.61143.b0

Similar Items

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2022-01-01)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
by: Evangelos Terpos, et al.
Published: (2022-02-01)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
by: Dimitris Papadopoulos, et al.
Published: (2022-01-01)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-07-01)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-08-01)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
by: Evangelos Terpos, et al.
Published: (2021-08-01)

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
by: Margherita Rosati, et al.
Published: (2022-11-01)

S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY
by: E. Terpos, et al.
Published: (2022-06-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Evangelos Terpos, et al.
Published: (2022-04-01)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
by: Foteini Theodorakakou, et al.
Published: (2023-06-01)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
by: Ioannis P. Trougakos, et al.
Published: (2021-08-01)

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
by: I. Ntanasis-Stathopoulos, et al.
Published: (2023-05-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
by: I. Ntanasis-Stathopoulos, et al.
Published: (2023-05-01)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
by: V. Spiliopoulou, et al.
Published: (2023-05-01)

Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations
by: Margherita Rosati, et al.
Published: (2023-11-01)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01)

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
by: P. Malandrakis, et al.
Published: (2023-05-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-07-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
by: Efstathios Kastritis, et al.
Published: (2023-11-01)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
by: Nikolaos Kanellias, et al.
Published: (2022-05-01)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
by: Efstathios Kastritis, et al.
Published: (2021-08-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
by: Cristina Bergamaschi, et al.
Published: (2021-08-01)

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
by: Ioannis V. Kostopoulos, et al.
Published: (2024-02-01)

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
by: Aristea-Maria Papanota, et al.
Published: (2021-07-01)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
by: Evangelos Terpos, et al.
Published: (2023-08-01)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
by: Maria Papatsirou, et al.
Published: (2023-08-01)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
by: Panagiotis Malandrakis, et al.
Published: (2023-08-01)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
by: Evangelos Terpos, et al.
Published: (2023-08-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
by: Maria Gavriatopoulou, et al.
Published: (2021-03-01)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-10-01)